Financings

Adverum Biotechnologies Inc. priced its public offering for gross proceeds of about $60 million.

Athersys Inc. established a follow-on equity facility with Aspire Capital Fund LLC, gaining the right to sell up to $100 million of its common stock to Aspire under certain conditions over a three-year period.

Cellular Biomedicine Group Inc. received a $30.6 million investment from Sailing Capital Overseas Investment Ltd. and its affiliates.

Cymabay Therapeutics Inc. closed its public offering of stock, selling 13.34 million shares, including the underwriters' option to purchase 1.74 million shares, for $10.80 per share.

Edmond De Rothschild has closed its fifth fund, Biodiscovery V, at €345 million (US$430 million), which it said is the largest biotech and medical devices venture fund to be raised in Europe.

Evolus Inc. priced its IPO of 5 million shares at $12 per share, the low end of its previously proposed range, for gross proceeds of $60 million.

Infant Bacterial Therapeutics AB raised SEK440 million (US$55.7 million) through a fully subscribed offering.

Medicinova Inc. priced an underwritten public offering with gross proceeds expected to be approximately $40 million.

Moderna Therapeutics Inc. raised $500 million from new U.S. and current institutional investors.

Sol-Gel Technologies Ltd. closed its IPO for gross proceeds of about $86.3 million.

Syros Pharmaceuticals Inc. closed its underwritten public offering of common stock for net proceeds of approximately $42.9 million.

Viking Therapeutics Inc. closed its underwritten public offering for gross proceeds of about $63.3 million.

Deals

Advanced Proteome Therapeutics Corp. and Immunobiochem Corp. signed a collaboration and option agreement to develop antibody-drug conjugates.

Anabios Corp. has formed a partnership with Sanofi SA to develop a new treatment for atrial fibrillation.

Anika Therapeutics Inc. entered an agreement with the Institute of Integrative Biology at the University of Liverpool to collaborate on research to develop an injectable mesenchymal stem cell therapy for the treatment of osteoarthritis.

Astellas Pharma Inc. and Pfizer Inc. are committing a total of $10 million in support to a new independent research project by the Breast Cancer Research Foundation to advance understanding of the role of the androgen receptor in breast cancer.

Canbridge Life Sciences Inc. licensed the exclusive rights to develop and commercialize Nerlynx (neratinib) in greater China from Puma Biotechnology Inc.

Geovax Labs Inc. is collaborating with Carogen Corp. on the development of a combination immunotherapy treatment for chronic hepatitis B virus infection.

Hemacare Corp. and Charles River Laboratories International Inc. said they formed a strategic partnership to advance human immune system research by developing a more efficient and reliable method of working with humanized mice.

Lonza Group Ltd. and Denali Therapeutics Inc. are partnering on Denali's biologic pipeline products for neurodegenerative diseases.

Netvation DL Medicine entered a research collaboration with Pfizer Inc. to produce new chemical entities against pre-selected targets from multiple therapeutic areas.

Rexahn Pharmaceuticals Inc. entered a collaboration and license agreement with Zhejiang Haichang Biotechnology Co. Ltd. to develop RX-0201 (Archexin) for the treatment of hepatocellular carcinoma.

. . . And More

Capricor Therapeutics Inc. said the FDA granted CAP-1002, its lead investigational cell therapy for the treatment of Duchenne muscular dystrophy, the regenerative medicine advanced therapy designation.

Paratek Pharmaceuticals Inc. said it completed the submission of two NDAs for its once-daily oral and intravenous formulations of broad-spectrum antibiotic omadacycline.

Sandoz GmbH said it received a complete response letter from the FDA in connection with its regulatory submission for a generic version of Advair (fluticasone propionate/salmeterol, Glaxosmithkline plc).

Santhera Pharmaceuticals AG has launched a U.S. expanded access program, known as BreatheDMD, with idebenone for patients with Duchenne muscular dystrophy.

Verastem Inc. submitted an NDA to the FDA for duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma.

Zogenix Inc. said the FDA granted breakthrough designation to ZX-008 (low-dose fenfluramine) for the treatment of seizures associated with Dravet syndrome.